ライフサイエンスコーパス: drug withdrawal

1 s is due to chronic effects, ongoing use, or drug withdrawal.

2 ndary motoneurons that is not ameliorated by drug withdrawal.

3 of 1 or more black box warnings per drug, or drug withdrawal.

4 ly) that returned to preinduction size after drug withdrawal.

5 oliferation persisted for several days after drug withdrawal.

6 duced graft survival after immunosuppressive drug withdrawal.

7 g calcium-permeable AMPARs (CP-AMPARs) after drug withdrawal.

8 e performed serially for up to 10 days after drug withdrawal.

9 evelopment as well as residual effects after drug withdrawal.

10 recovery was evident within 3 days following drug withdrawal.

11 nded to either immunomodulating therapies or drug withdrawal.

12 relapse effects of EE can be unleashed after drug withdrawal.

13 ional state may exist between depression and drug withdrawal.

14 ) and elicits negative affective states upon drug withdrawal.

15 levels similar to the healthy controls after drug withdrawal.

16 on symptoms in chronic drug users long after drug withdrawal.

17 ations in reward valuation during protracted drug withdrawal.

18 is unpredictable and almost always leads to drug withdrawal.

19 eizures, an effect that persists weeks after drug withdrawal.

20 nib, 100% of the diseased mice relapsed upon drug withdrawal.

21 l biopsies performed up to 3 years following drug withdrawal.

22 idepressant effect was still seen 2 wk after drug withdrawal.

23 oing colistin treatment, and upon subsequent drug withdrawal.

24 as been implicated in negative affect during drug withdrawal.

25 duced liver injury (DILI) is a main cause of drug withdrawal.

26 lammation and also ameliorate the effects of drug withdrawal.

27 l population, an effect that was reversed on drug withdrawal.

28 gic EPSC frequency persisted 10-20 min after drug withdrawal.

29 owed regrowth of the tumor vasculature after drug withdrawal.

30 seizure susceptibility, a common symptom of drug withdrawal.

31 tological features should be normal prior to drug withdrawal.

32 and neural consequences following 2 weeks of drug withdrawal.

33 Drd1-EGFP-positive neurons after 30 days of drug withdrawal.

34 predictive of the viral RNA set point after drug withdrawal.

35 on the negative affective state after acute drug withdrawal.

36 in Drd1-EGFP-positive neurons 30 days after drug withdrawal.

37 ients and their providers about an important drug withdrawal.

38 the antagonist MK801, and accelerates after drug withdrawal.

39 prognostic value in predicting relapse after drug withdrawal.

40 adaptations remain unopposed and may lead to drug withdrawal.

41 ment in myocardial pathology after inotropic drug withdrawal.

42 e peripheral and is usually reversible after drug withdrawal.

43 imals ultimately rejected their grafts after drug withdrawal.

44 eases in development costs, and high-profile drug withdrawals.

45 , seizure-free interval before antiepileptic drug withdrawal, age at onset of epilepsy, history of fe

46 blood samples obtained before initiation of drug withdrawal and at rejection, alongside blood sample

47 2 T cell recovery correlated with time since drug withdrawal and inversely correlated with patient ag

48 eloped fluid retention, which reversed after drug withdrawal and presented predominantly as periphera

49 the aversive motivational state produced by drug withdrawal and the development of the drug-dependen

50 d by DDC refeeding lasted for 4 months after drug withdrawal and was not manifest when SAMe was added

51 about the mechanism by which MPDZ influences drug withdrawal and/or other CNS hyperexcitability state

52 d into several sections: the first describes drug withdrawals and new general reviews of drug-induced

53 ntihypertensive agents, in the management of drug withdrawal, and as sedative analgesics.

54 s have just completed or are in the midst of drug withdrawal, and four patients were not withdrawn du

55 pecimens from 27 long-term recipients before drug withdrawal, and from 10 patients with recent transp

56 ls in the viral RNA set point after complete drug withdrawal, and none of the animals was able to ach

57 are an integral part of acute and protracted drug withdrawal, and several lines of evidence have show

58 of +/- cells failed to reach anaphase after drug withdrawal, and those that entered anaphase showed

59 The frequencies of remission, relapse after drug withdrawal, and treatment failure were comparable i

60 on the premise that repeated relapses after drug withdrawal are inevitable.

61 Although long-lasting effects of drug withdrawal are thought to play a key role in motiva

62 e inhibitors (TKIs) underwent apoptosis upon drug withdrawal as a consequence of ERK1/2 hyperactivati

63 rring only with physiological stress such as drug withdrawal) at 2 years and 5 years after surgery on

64 d Drd2-EGFP-positive neurons after 2 days of drug withdrawal but only in Drd1-EGFP-positive neurons a

65 the chromatin structure were reversible upon drug withdrawal, but obligatory for the potentiation of

66 ression converted to sirolimus, and complete drug withdrawal by 24 months post-transplantation.

67 though aLQTS has become the leading cause of drug withdrawal by the U.S.

68 QT syndrome (aLQTS), is a leading cause for drug withdrawal by the United States Food and Drug Admin

69 a prospective multicenter immunosuppressive drug withdrawal clinical trial.

70 After drug withdrawal, cocaine-generated silent synapses becam

71 viously implicated in both schizophrenia and drug withdrawal delirium, exhibited frequent replacement

72 cell cycle, and differentiated normally upon drug withdrawal, demonstrating reversibility of the effe

73 Incidence of side-effects and drug withdrawals did not differ by much between the two

74 te (DDC) for 10 weeks followed by 1 month of drug withdrawal (drug-primed mice) and then 7 days of dr

75 emission, time to first seizure, and time to drug withdrawal due to inadequate seizure control or sid

76 rapy, time to 12-month remission, or time to drug withdrawal due to unacceptable side-effects or to l

77 Drug withdrawal effects on negative symptom factors were

78 trate that nicotine exposure, independent of drug withdrawal effects, increases stress sensitivity, a

79 One day after drug withdrawal, endothelial sprouts grew into empty sle

80 facilitate prediction of outcomes following drug withdrawal for the individual patient, including bo

81 us joint-action analysis to investigate poly-drug withdrawal from fixed-ratio cocaine/kappa-opioid ag

82 ver injury (DILI) remains a leading cause of drug withdrawal from human clinical trials or the market

83 re found to be reversible within 24 hours of drug withdrawal from the cell culture media.

84 sible for over 60% of black box warnings and drug withdrawals from the market place in the United Sta

85 re in clinical trials and a major reason for drug withdrawals from the market.

86 Following 8 weeks of drug withdrawal, HAL-induced changes in brain volumes no

87 The consequences that drug withdrawal has on immune functioning has only recen

88 on protocols with complete immunosuppressive drug withdrawal have been tested in humans.

89 olecular pathways associated with successful drug withdrawal, however, are not well defined.

90 acement therapy and management of iatrogenic drug withdrawal in ICU patients.

91 Symptom exacerbation induced by drug withdrawal in patients with treatment-resistant sch

92 withdrawal of rofecoxib, one of the largest drug withdrawals in United States history, and instruct

93 (BNST), each of which has been implicated in drug-withdrawal-induced anxiety and stress-induced respo

94 ism underlying the relapse to drug use after drug withdrawal is largely unknown.

95 ssists in identifying those patients in whom drug withdrawal is likely to be unsuccessful and in whom

96 icts that the first step in the induction of drug withdrawal is the activation of reward-related circ

97 epressive effects) in rats and humans (e.g., drug withdrawal, kappa-opioid agonists).

98 Earlier recognition and drug withdrawal may avoid the serious and sometimes fata

99 ng age and treatment duration, antiepileptic drug withdrawal may be justified.

100 Aspects of drug withdrawal may become conditioned to previously neu

101 al output and suggest one mechanism by which drug withdrawal may influence limbic dopamine-dependent

102 ntipsychotic agents and the possibility that drug withdrawal may negatively affect subsequent drug re

103 , seizure-free interval before antiepileptic drug withdrawal, number of antiepileptic drugs before wi

104 icant bradycardia/hypotension, necessitating drug withdrawal, occurred in 2 of 40 (5%) patients on so

105 ee times normal), all of which reversed with drug withdrawal, occurred in five patients (P=.03 vs pla

106 Understanding the consequences of drug withdrawal on immune function and host defense to i

107 Before initiation of drug withdrawal, operationally tolerant and non-tolerant

108 ommon variation influences either seizure or drug withdrawal outcomes after initiation of antiepilept

109 used negative symptom ratings obtained in a drug withdrawal paradigm to compare symptom profiles in

110 re in hypertension, reduction in alcohol and drug withdrawal phenomena, reduction in nicotine withdra

111 s prompted a previously reported prospective drug withdrawal program in 59 liver recipients.

112 After drug withdrawal, reemergence of clonal EGFR mutations on

113 nference, liver for up to 6 months following drug withdrawal required a replication efficiency of at

114 ere unable to complete DNA replication after drug withdrawal, resulting in lethality.

115 A-type glutamate receptors (CP-AMPARs) after drug withdrawal results in profound remodeling of NAc ne

116 seizures, the diagnosis excluding alcohol or drug withdrawal seizures or such recurring exogenous eve

117 orly understood, and strategies for complete drug withdrawal should be selected carefully to avoid gr

118 Drug-withdrawal stressors, related to long-term pharmaco

119 t of primary NSCLC, and they persisted after drug withdrawal, suggesting the benefits were durable.

120 Drug administration to avoid unpleasant drug withdrawal symptoms has been hypothesized to be a c

121 for alleviating incisional pain and narcotic drug withdrawal symptoms, which are now in clinical tria

122 gs of abuse and the manifestations of opiate/drug withdrawal symptoms.

123 tal abstinence syndrome (NAS) is a postnatal drug withdrawal syndrome primarily caused by maternal op

124 dence of the neonatal abstinence syndrome, a drug-withdrawal syndrome that most commonly occurs after

125 euromuscular blockers, pain assessments, and drug withdrawal syndromes were gathered during the first

126 rigorously tested in comparative studies of drug withdrawal treatment; their use as additional or al

127 Disease recurrence during drug withdrawal was documented in 2 of 13 patients with

128 Y/F zidovudine resistance mutation following drug withdrawal were estimated to be 96 to 98% that of t

129 Psychiatric disorders, drug use or drug withdrawal were rarely causally related to RBD.

130 pirin and the kinetics of its recovery after drug withdrawal were similar in patients and control sub

131 expression is dramatically increased during drug withdrawal, which would suggest a direct connection